| P2093 | author name string | Sailaja Kesiraju | |
| | S Sahariah | |
| | Praneeth Srikanti | |
| P2860 | cites work | Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q21534928 |
| | Novel Role of Toll-Like Receptor 3 in Hepatitis C-Associated Glomerulonephritis | Q27477518 |
| | Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 |
| | Relationship of hepatitis B or C virus prevalences, risk factors, and outcomes in renal transplant recipients: analysis of German data | Q31159237 |
| | Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group | Q33464499 |
| | Blood-borne virus infections in dialysis units--a review | Q33673970 |
| | Renal transplantation in patients with hepatitis C virus antibody. A long national experience | Q33871282 |
| | Transplantation in the patient with hepatitis C. | Q33948874 |
| | Impact of hepatitis C virus infection on the risk of infectious complications after kidney transplantation: data from the RESITRA/REIPI cohort. | Q34003488 |
| | Antiviral strategies in hepatitis C virus infection | Q34251454 |
| | Complementary and alternative medications in hepatitis C infection. | Q34411345 |
| | Effect of kidney transplantation on outcomes among patients with hepatitis C | Q35012447 |
| | Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety | Q35182193 |
| | The impact of Hepatitis C virus infection on kidney transplantation outcomes: A systematic review of 18 observational studies: The impact of HCV on renal transplantation. | Q35507756 |
| | Hepatitis C virus infection and renal disease after renal transplantation | Q35757112 |
| | Hepatitis C virus infection and kidney disease: a meta-analysis | Q35860681 |
| | Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). | Q35877908 |
| | Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies | Q35911859 |
| | Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies | Q36257275 |
| | Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models | Q36399860 |
| | Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting | Q36668891 |
| | Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms | Q37063767 |
| | Hepatitis C virus and kidney disease | Q37229019 |
| | Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials | Q37718739 |
| | Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection. | Q37771802 |
| | Hepatitis C and renal transplantation | Q38056637 |
| | Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies | Q38231457 |
| | Hepatitis C and its impact on renal transplantation | Q38341218 |
| | Hepatitis C infection and post-transplantation liver disease. | Q40448305 |
| | Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes | Q40622941 |
| | Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study | Q40957442 |
| | Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment | Q42172370 |
| | Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial | Q42251577 |
| | Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. | Q42979080 |
| | The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study | Q42982319 |
| | Prevalence of HCV infection in patients on haemodialysis: survey by antibody and core antigen detection | Q42992881 |
| | Hepatitis C virus RNA in kidney biopsies from infected patients with renal diseases | Q42997743 |
| | Impact of hepatitis C virus infection on renal transplant outcome in India--a single centre study. | Q43030676 |
| | Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation. | Q43032343 |
| | The impact of hepatitis C virus infection on renal allograft recipients | Q43035502 |
| | Outcome of kidney transplant in chronic hepatitis C virus patients: effect of pretransplantation interferon-alpha2b monotherapy | Q43046624 |
| | Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation | Q43047599 |
| | Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand | Q44177155 |
| | Hepatitis C and renal transplantation in the era of modern immunosuppression | Q44625419 |
| | Is hepatitis C a risk factor to posttransplant diabetes mellitus after renal transplantation in patients using tacrolimus? | Q44934202 |
| | Hepatitis C virus infection and de novo glomerular lesions in renal allografts | Q45731872 |
| | Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. | Q46741311 |
| | Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? | Q50550498 |
| | Subclinical Rejection Associated with Chronic Allograft Nephropathy in Protocol Biopsies as a Risk Factor for Late Graft Loss | Q62619830 |
| | The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients | Q73215922 |
| | Clinical outcome of HCV infection after renal transplantation | Q73304383 |
| | Severe evolution of chronic hepatitis C in renal transplantation: a case control study | Q77438904 |
| | Risk factors for development of new-onset diabetes mellitus after kidney transplantation | Q79468593 |
| | Hepatitis C, acute humoral rejection, and renal allograft survival | Q81096274 |
| | Risk factors and outcomes of new-onset diabetes after transplant: single-centre experience | Q84923089 |
| | Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease | Q85415636 |
| P433 | issue | 3 | |
| P304 | page(s) | 233-241 | |
| P577 | publication date | 2017-08-24 | |
| P1433 | published in | VirusDisease | Q26842366 |
| P1476 | title | Hepatitis C infection in renal transplantation: pathogenesis, current impact and emerging trends | |
| P478 | volume | 28 | |